Since the discovery last century of the role of the immune system in 
) and the inhibitory CD94-NKG2A heterodimeric receptors that bind the non-classic MHC class Ib (HLA-E). Another inhibitory NK receptor is the C-type lectin-like receptor NKR-P1A (CD161) that interacts with lectin-like transcript-1, a hostencoded non-MHC ligand. NK cells also express activating receptors such as the natural cytotoxicity receptors (NCRs) NKp30, NKp44 and NKp46. NK cell function is thus governed by both inhibitory and activating surface receptors.
It has been shown that NK cells can lyse the different subtypes of leukaemia or leukaemic cell lines, but the mechanisms underlying the interaction and destruction of these cells are not clearly defined (see Figure 1 ).
In AML patients, NK cell activity correlates positively with relapse-free survival, which suggests that NK cells may play an important role in the control and clearance of leukaemia. 12 On the other hand, the activity of autologous NK cells against leukaemic cells is frequently reduced 13 and abnormalities of NK cell phenotype or activity during leukaemia have recently been identified. 14 A variety of escape mechanisms to the immune system and especially NK cells have been found in AML patients and are described below.
Inhibitory Receptors and Acute Myeloid Leukaemia
There is a dominance of inhibitory over-activating signals in leukaemic patients. 15 Deficient HLA class I expression (reduced expression or loss of HLA class I alleles) has been described in malignant cells. HLA class I molecules belonging to the Bw6 group were more frequently downregulated than those belonging to the HLA-Bw4 group. 16 However, until now the expression of the ligands for KIR2DL4 and NKG2A, namely HLA-G or HLA-E, has not been demonstrated on leukaemic cells. 16 
Activatory Receptors and Acute Myeloid Leukaemia
Defective cytotoxicity of AML cells can be explained by abnormalities of activating NK receptor expression. 14 In vitro data show that NCRs mediate NK-dependent leukaemia cell lysis. 17, 18 We have demonstrated that the majority of NK cells in AML patients display an abnormal phenotype characterised by a downregulation of NKp30 and NKp46
NCR that correlates with a defective cytolytic function against autologous AML cells (NCR-dull). 18 Interestingly, the NCR surface density is restored completely (NKp46) or partially (NKp30) when a complete remission is obtained with chemotherapy. 19 In addition, there is defective killing of dendritic cells by autologous NK cells from AML patients, which may contribute to leukaemia escape. 20 Finally, a correlation between the downregulation of NCR and shorter survival was seen in AML patients. 19 The putative NCR ligands that are expressed during the maturation of normal myelo-monocytic cells have weak expression on AML blasts. 21 The expression of NKG2D ligands by leukaemic cells has been observed by Salih et al., 22 but not by Pende et al. 23 A recent study has showed the expression of NKG2D ligands on AML blasts at diagnosis but only on AML of M4 and M5 subtypes 24 (see Figure 2) Anti-natural Killer Inhibitory Receptors in Elderly Patients with Acute Myeloid Leukaemia reduced relapse rate. 31 In another study, high NK counts at day 30
were associated with improved outcomes in patients with acute leukaemia who received T-cell-depleted allografts. 32 Altogether, these data demonstrate that NK cells are readily present early following HSCT and are likely candidates to exert their functions against AML blasts. Unfortunately, due either to its toxicity or to the lack of a suitable donor, allo-HSCT can only be offered to a minority of patients, and this is particularly true for elderly patients.
Targeting KIRs Using Monoclonal Antibodies

Description of Anti-KIR Ab
Are there ways to therapeutically design agents that would mimick haplo-identical therapy? One approach is based on therapeutic use of mAb targeting the inhibitory receptors. [33] [34] [35] The ideal mAb candidate characteristics are:
• recognition of most if not all inhibitory receptors present on patients' NK cells;
• discrimination between inhibitory KIR (with a long intra-cytoplasmic tail (KIR* L*) and activating KIR (with a short intra-cytoplasmic tail (KIR*DS*);
• absence of KIR expression down-modulation to allow for a longterm effect; and
• absence of complement or antibody-dependent cellular cytotoxicity (ADCC) activation in order to avoid NK depletion.
A first generation of these mAbs has been devised. 36 Geriatric Oncology 
Pre-clinical and Clinical Experience with 1-7f9 Anti-KIR Monoclonal Antibodies
Animal Models
KIRs are not expressed in mice. These animals use a family of inhibitory Ly49 receptors for recognition of MHC class I allotypes on target cells. Therefore, the in vivo effects of 1-1-7F9/IPH2101 mAb were evaluated using two different approaches in humanised mice. 
Future Developments
The and their receptors is not restricted to AML. For instance, multiple myeloma cells are sensitive to NK-cell attack. 38 In vitro, 1-7F9/IPH2101
was able to induce interferon (INF) and granzyme B release from NK cells against autologous myeloma cells. 39 In an ongoing phase I study, 14 patients with advanced refractory or relapsed myeloma have been treated with escalating doses of 1-7F9/IPH2101. In this population, as in elderly patients, the antibody was safe and well tolerated.
Pharmacokinetic as well as KIR occupancy data were comparable to those in the AML trial. 39 However, it is likely that 1-7F9/IPH2101 as a single agent will not be enough to achieve disease control. In this regard, its combination could be reinforced by the combination with 1-7F9/IPH2101. In addition, these strategies make it possible to treat patients with active disease, since they allow control of the disease burden while not impairing immune function, as is the case for conventional cytotoxic agents. 43 Future directions for the use of 1-7F9/IPH2101 are presented in Table 2 . 
Conclusions and Questions
